Monday, September 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyzing Viking Therapeutics Stock Performance and Buyback Initiatives

Elaine Mendonca by Elaine Mendonca
March 11, 2024
in Breaking News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Viking Therapeutics (VKTX) stock has been on a rollercoaster ride, dropping by 10.9% on a recent Monday afternoon. This dip comes after significant company updates in February, such as meeting Phase 2 VENTURE trial goals and a public offering of common shares at $85 each.

When considering whether VKTX is a worthwhile investment, factors like valuation, price movements, and capital allocation strategies come into play. While Viking Therapeutics doesn’t offer dividends, they can still create value for shareholders through various methods. Recently, the company implemented a buyback initiative, which could help boost share prices by boosting demand.

On March 10, 2022, Viking Therapeutics’ Board of Directors approved a buyback program. Between April 1, 2022, and June 30, 2022, the company repurchased over 700,000 shares for $1.66 million. Furthermore, in March 2020, Viking Therapeutics unveiled a buyback plan totaling up to $50 million over two years.

These buyback schemes can impact investor confidence and stock prices by showcasing faith in the company’s worth and potentially providing a safety net for share values.

VKTX Stock Plummets 11.79% on March 11, 2024: Analysis and Outlook

On March 11, 2024, VKTX stock experienced a significant drop in its price performance. According to data from CNN Money, the stock opened at $69.94, which was $1.84 lower than its previous close. Throughout the trading day, the price of VKTX shares continued to decline, ultimately dropping by $8.46, or 11.79%.

Despite this sharp decrease in price, VKTX is still trading in the middle of its 52-week range and is currently above its 200-day simple moving average. This suggests that while the stock may have experienced a short-term decline, it is still performing relatively well compared to its historical performance and long-term trend.

VKTX Stock Performance Analysis: Net Income and EPS Trends – March 11, 2024

On March 11, 2024, VKTX stock showed mixed performances based on the financial data available. The company’s net income for the past year was reported at -$85.89 million, with a decrease of 24.73% compared to the previous year. In the last quarter, VKTX’s net income was -$24.61 million, showing a slight increase of 0.0% compared to the previous quarter.

Similarly, the earnings per share (EPS) for VKTX were reported at -$0.91 for the past year, reflecting a 1.57% increase compared to the previous year. In the last quarter, the EPS was reported at -$0.25, showing no change compared to the previous quarter.

Investors and analysts may want to closely monitor VKTX’s financial reports and any updates on its total revenue to gain a better understanding of the company’s overall financial health and future prospects. As with any investment, it is important to conduct thorough research and analysis before making any decisions regarding VKTX stock.

Tags: VKTX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Biotechnology Stock Bull Market

Options Activity Analysis for Cloudflare NYSE NET

Insurance company Stock Market Today

Legal Action Initiated by James River Group Holdings to Enforce Stock Purchase Agreement against Fleming Intermediate Holdings

Healthcare-IT-and-tech

Analysts Bullish on Sotera Health with Strong Buy Rating and Upward Price Targets

Recommended

Emergent BioSolutions Stock

A Tale of Two Realities: Emergent BioSolutions’ Social Mission and Financial Strain

4 weeks ago
Food Retailers Stock Bull Market

JP Morgan Analyst Maintains Neutral Rating on Tyson Foods with Revised Price Target

2 years ago
MMM stock news

Bearish Sentiment Surrounds Air Lease NYSE AL Trading

2 years ago
QuantumScape Stock

QuantumScape Leadership Executes Major Stock Sales, Raising Investor Concerns

5 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Ubiquiti Shares Reach New Heights on Product Expansion Momentum

BioNTech’s Strategic Pivot: From Pandemic Success to Oncology Innovation

Leadership Crisis at Nestlé Sparks Investor Concerns

Standex Shares Plunge Amid Technical Warnings and Insider Selling

Navigating Credit Headwinds: Synchrony’s Strategic Expansion Amid Sector Challenges

Tech Sector Surge: AI and Cloud Computing Fuel Vanguard ETF’s Record Run

Trending

Pfizer Stock
Healthcare

Pfizer’s Strategic Gambit: A $7.3 Billion Entry into the Weight-Loss Arena

by Dieter Jaworski
September 22, 2025
0

In a move signaling its serious intent to capture a share of the lucrative anti-obesity drug market,...

Nike Stock

Nike Shares Face Critical Earnings Test

September 22, 2025
Tutor Perini Stock

Insider Sales at Tutor Perini Coincide with Stock Peak

September 22, 2025
Ubiquiti Stock

Ubiquiti Shares Reach New Heights on Product Expansion Momentum

September 22, 2025
BioNTech Stock

BioNTech’s Strategic Pivot: From Pandemic Success to Oncology Innovation

September 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pfizer’s Strategic Gambit: A $7.3 Billion Entry into the Weight-Loss Arena
  • Nike Shares Face Critical Earnings Test
  • Insider Sales at Tutor Perini Coincide with Stock Peak

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com